The increasingly competitive nature of the market for biopharmaceuticals is exacerbating the need for greater cost efficiency within the industry. This chapter describes how biomanufacturers can streamline early-stage development and rapidly configure a standard and well-qualified manufacturing single-use process by adopting the platform approach. Single-use platforms are available for a wide range of biological entities including mAbs, viral vectors, antibody-drug conjugates, and regenerative medicines. Single-use facilities require a lower capital investment than their multiuse stainless steel equivalents even if the costs of consumables are higher. Learn More